Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02117648 · ClinicalTrials.gov registry record · Phase 1

A Study of LY2835219 in Participants With Cancer

A Phase 1 study of Neoplasm Metastasis and Neoplasm, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
2
Study locations

NCT02117648 is a Phase 1 study of Neoplasm Metastasis and Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02117648, a Phase 1 study of Neoplasm Metastasis and Neoplasm, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied. Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.

Conditions Studied

Neoplasm Metastasis Neoplasm

Interventions

  • DRUG Abemaciclib
  • DRUG Clarithromycin

Study Locations (2)

Tennessee

  • Accelerated Comm. Oncology Research Network (ACORN) - Memphis
  • The West Clinic - Memphis

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2014-04
Est. Completion 2015-08
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02117648

The ClinicalTrials.gov registry entry for NCT02117648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.

NCT02117648 reports 2 study locations spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT02117648 about?

NCT02117648 is a clinical study titled "A Study of LY2835219 in Participants With Cancer". The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety ...

What is the current status of trial NCT02117648?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-04. Estimated completion is 2015-08.

What conditions does trial NCT02117648 study?

This clinical trial studies the following conditions: Neoplasm Metastasis, Neoplasm.

What interventions are being tested in trial NCT02117648?

The interventions under investigation include: Abemaciclib (DRUG), Clarithromycin (DRUG).

Who is sponsoring clinical trial NCT02117648?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02117648 being conducted?

This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Metastasis

All registered trials for this condition

Neoplasm

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.